Extended indication Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure with reduced
Therapeutic value No estimate possible yet
Total cost 2,455,000.00
Registration phase Positive CHMP opinion

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information